Equities

Genoway SA

Genoway SA

Actions
  • Price (EUR)3.19
  • Today's Change-0.26 / -7.54%
  • Shares traded0.00
  • 1 Year change-18.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genoway SA is a France-based company which is specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.

  • Revenue in EUR (TTM)21.42m
  • Net income in EUR1.26m
  • Incorporated1999
  • Employees128.00
  • Location
    Genoway SATechnopark 2, 31 Rue Saint Jean-de-DieuLYON 69007FranceFRA
  • Phone+33 437654100
  • Fax+33 437654101
  • Websitehttps://www.genoway.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.